Success Metrics

Clinical Success Rate
40.0%

Based on 2 completed trials

Completion Rate
40%(2/5)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
3(43%)

Phase Distribution

Ph phase_1
2
29%
Ph phase_2
3
43%
Ph phase_3
2
29%

Phase Distribution

2

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

2 of 6 finished

Non-Completion Rate

66.7%

4 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(2)
Terminated(4)
Other(1)

Detailed Status

Terminated3
Completed2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
40.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 23 (42.9%)
Phase 32 (28.6%)

Trials by Status

completed229%
unknown114%
terminated343%
withdrawn114%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_2

Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

NCT00170573
terminatedphase_1

TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors

NCT03387917
unknownphase_2

CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER

NCT03712956
terminatedphase_3

A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

NCT01840943
withdrawnphase_1

Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas

NCT01490047
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT00170573Phase 2

Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

Completed
NCT03387917Phase 1

TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors

Terminated
NCT03712956Phase 2

CAELYX® as Adjuvant Treatment in Early Stage Luminal B Breast Cancer BREAST CANCER

Unknown
NCT01840943Phase 3

A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Terminated
NCT01490047Phase 1

Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas

Withdrawn
NCT00284336Phase 2

Caelyx Adjuvant in Elderly Breast Cancer

Completed
NCT00653952Phase 3

CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7